A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Hematologic Diseases Clinical Trial

Official title:

A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4172239D

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05660265
• Other study ID #: 218471
• Status: Recruiting
• Phase: Phase 1
• Start date: August 26, 2023
• Est. completion date: March 11, 2025

Study information

• Verified date: November 2023
• Source: GlaxoSmithKline
• Contact: US GSK Clinical Trials Call Center
• Phone: 877-379-3718
• Email: GSKClinicalSupportHD[@]gsk.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a first time in human (FTIH) study in sickle cell diseases (SCD) participants. The FTIH study is planned to evaluate the safety, tolerability, and pharmacokinetics of GSK4172239D.

The study will be composed of 3 periods for all participants (Screening, Treatment, and Follow up). Participants will be screened and, prior to first dose on Day 1, will be randomized to receive either GSK4172239D or placebo.

GSK4172239D is a prodrug that is converted in vivo into GSK4106401. This study will be a single dose, dose-escalation study. The initial dosing for all cohorts will be staggered so that 2 participants will be dosed as sentinel participants. Provided there are no safety concerns in 48 hours (h), the remaining 6 participants scheduled for the cohort may be dosed. One selected cohort of participants will also receive an additional single dose of GSK4172239D (or matching placebo) under fed (high calorie and high fat) conditions after a washout period of a minimum of 20 days or 5 half-lives, whichever is longer, designated as the Food Effect Cohort.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: March 11, 2025
• Est. primary completion date: March 11, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion criteria:

• Participants diagnosed with SCD not taking medication which increases gamma-globin (fetal hemoglobin).

• Participants with SCD who have failed or not tolerated one or more approved therapies for SCD

• Body weight greater than (>) 50 kilogram (kg).

• For male participants: Refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent. OR agree to use a male condom with female partner. Agree to use an additional highly effective contraceptive method with a failure rate of less than (<) 1% per year when having sexual intercourse with a woman of childbearing potential who is not currently pregnant

• For female participants: Female participants are eligible to participate if they are a woman of non-childbearing potential (WONCBP).

• Capable of giving informed consent.

Exclusion Criteria:

• Presence of active, clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data.

• Clinically significant abnormal blood pressure and/or history of hypertension as determined by the investigator.

• History of clinically significant heart disease as determined by the investigator.

• Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m^2

• ALT > 3x upper limit of normal (ULN).

• Bilirubin > 5x ULN (isolated bilirubin > 5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).

• Hemoglobin < 6 gram/decalitre (g/dL).

• Absolute neutrophil count <1,500 / microlitre (µL).

• Platelet count <75,000 /µL or >750,000 /µL.

• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 t1/2 (whichever is longer) prior to the first dose of study drug, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise participant safety. By exception, participant may take acetaminophen (less than or equal to [=] 2 g/day) up to 48h prior to the first dose of study drug.

• Use of hydroxyurea or decitabine within 9 weeks prior to baseline through follow-up.

• Blood transfusion within 3 months prior to baseline through follow-up.

• Current enrollment or past participation within the last 30 days before signing of consent in this or any other clinical study involving an investigational study drug or any other type of medical research.

• Positive pre-study drug/alcohol screen. By exception, opioid use for pain or benzodiazepine use for anxiety as directed by a physician is permitted.

• Regular use of known drugs of abuse, except for use directed by a physician. By exception, opioid use for pain or benzodiazepine use for anxiety is permitted.

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Hematologic Diseases

Intervention

Drug:
• GSK4172239D
Different strength of GSK4172239D will be administered in different cohorts.

Other:
• Placebo
Matching placebo will be administered.

Locations

Country	Name	City	State
United States	GSK Investigational Site	Atlanta	Georgia
United States	GSK Investigational Site	Columbus	Georgia
United States	GSK Investigational Site	Douglasville	Georgia
United States	GSK Investigational Site	Greenville	South Carolina
United States	GSK Investigational Site	Houston	Texas
United States	GSK Investigational Site	Las Vegas	Nevada
United States	GSK Investigational Site	Los Angeles	California
United States	GSK Investigational Site	Miami	Florida
United States	GSK Investigational Site	Miami	Florida
United States	GSK Investigational Site	Raleigh	North Carolina
United States	GSK Investigational Site	South Miami	Florida
United States	GSK Investigational Site	Tamarac	Florida

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under curve zero to time infinity (AUC 0-inf) for GSK4106401 after a single oral dose of GSK4172239D		Up to Day 3
Primary	Maximum observed plasma concentration (Cmax) for GSK4106401 after a single oral dose of GSK4172239D		Up to Day 3
Primary	Time to Cmax (Tmax) for GSK4106401 after a single oral dose of GSK4172239D		Up to Day 3
Primary	Half-life (t1/2) for GSK4106401 after a single oral dose of GSK4172239D		Up to Day 3
Primary	Ratio between the fed and fasted conditions for AUC (0-inf)		Up to Day 3
Primary	Ratio between the fed and fasted conditions for Cmax		Up to Day 3
Secondary	Number of participants with clinically significant changes from baseline in white blood cell (WBC)		Baseline and up to Day 7
Secondary	Number of participants with clinically significant changes from baseline in hemoglobin		Baseline and up to Day 7
Secondary	Number of participants with clinically significant changes from baseline in platelets count		Baseline and up to Day 7
Secondary	Number of participants with clinically significant changes from baseline in neutrophil count		Baseline and up to Day 7
Secondary	Number of participants with clinically significant changes from baseline in alanine transaminase (ALT)		Baseline and up to Day 7
Secondary	Number of participants with clinically significant changes from baseline in aspartate transaminase (AST)		Baseline and up to Day 7
Secondary	Number of participants with clinically significant changes from baseline in bilirubin		Baseline and up to Day 7
Secondary	Number of participants with adverse event (AE) and serious adverse event (SAE)		Up to Day 7
Secondary	Number of participants with clinically significant change from baseline in 12 lead electrocardiograms (ECG)		Baseline and up to Day 7
Secondary	Number of participants with clinically significant change from baseline in vital signs		Baseline and up to Day 7